CTIS2024-512215-53-00进行中（未招募）1 期
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study - MK-8591A-033
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 820
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Is currently receiving DOR 100 mg/ISL 0.75 mg adult fixed dose combination (FDC) tablet in an MSD-sponsored clinical study and has completed the last treatment visit., Is considered by the investigator to have derived clinical benefit from receiving DOR/ISL and for whom further treatment with DOR/ISL is considered clinically appropriate., Is male or female and =35 kg at the time of signing the informed consent/assent., Female is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP); or is a non-pregnant WOCBP who agrees to the following during the intervention period and for at least 6 weeks after the last dose of study intervention: Not be sexually active, or if sexually active, to use an acceptable method of contraception; or is pregnant and continues to receive study intervention (where allowed by local regulations and as appropriate based on available data/local standard-of-care guidelines).
排除标准
- •Is taking or is anticipated to require any prohibited therapies.
研究者
相似试验
进行中（未招募）
1 期
A study of MK8591A (DOR/ISL) for patients who have already been on DOR/ISL in previous studiesEUCTR2020-001191-14-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,000
进行中（未招募）
3 期
Open-label, Follow-up of DOR/ISL for HIV-1 InfectioJPRN-jRCT2031210528Tanaka Yoshiyuki32
进行中（未招募）
1 期
A study of MK8591A (DOR/ISL) for patients who have already been on DOR/ISL in previous studiesHIV-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2020-001191-14-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,000
进行中（未招募）
1 期
A study of MK8591A (DOR/ISL) for patients who have already been on DOR/ISL in previous studiesEUCTR2020-001191-14-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,000
进行中（未招募）
1 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AHemophilia AEUCTR2020-002215-22-IEBioverativ Therapeutics Inc.267